Sangamo Therapeutics Inc. (NASDAQ:SGMO) has a beta value of 1.65 and has seen 0.9 million shares traded in the last trading session. The company, currently valued at $1.50B, closed the last trade at $10.08 per share which meant it lost -$0.26 on the day or -2.51% during that session. The SGMO stock price is -92.76% off its 52-week high price of $19.43 and 11.21% above the 52-week low of $8.95. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.09 million shares traded. The 3-month trading volume is 956.58K shares.
The consensus among analysts is that Sangamo Therapeutics Inc. (SGMO) is an Overweight stock at the moment, with a recommendation rating of 2.10. 0 analysts rate the stock as a Sell, while 1 rate it as Overweight. 2 out of 10 have rated it as a Hold, with 7 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -$0.31.
Sangamo Therapeutics Inc. (NASDAQ:SGMO) trade information
Sporting -2.51% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on Friday, 09/03/21 when the SGMO stock price touched $10.08 or saw a rise of 2.8%. Year-to-date, Sangamo Therapeutics Inc. shares have moved -35.41%, while the 5-day performance has seen it change 0.90%. Over the past 30 days, the shares of Sangamo Therapeutics Inc. (NASDAQ:SGMO) have changed 1.10%. Short interest in the company has seen 13.73 million shares shorted with days to cover at 18.41.
Wall Street analysts have a consensus price target for the stock at $20.67, which means that the shares’ value could jump 51.23% from current levels. The projected low price target is $11.00 while the price target rests at a high of $30.00. In that case, then, we find that the current price level is -197.62% off the targeted high while a plunge would see the stock gain -9.13% from current levels.
Sangamo Therapeutics Inc. (SGMO) estimates and forecasts
Figures show that Sangamo Therapeutics Inc. shares have underperformed across the wider relevant industry. The company’s shares have lost -7.35% over the past 6 months, with this year growth rate of -46.67%, compared to 7.50% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2021 fiscal year revenue. Growth estimates for the current quarter are -19.20% and -3,300.00% for the next quarter. Revenue growth from the last financial year stood is estimated to be -10.00%.
10 analysts offering their estimates for the company have set an average revenue estimate of $26.48 million for the current quarter. 9 have an estimated revenue figure of $25.19 million for the next quarter concluding in Sep 2021.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -9.10% over the past 5 years.
Sangamo Therapeutics Inc. is expected to release its next earnings report between November 02 and November 08 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Sangamo Therapeutics Inc. (NASDAQ:SGMO)’s Major holders
Insiders own 17.34% of the company shares, while shares held by institutions stand at 56.10% with a share float percentage of 67.87%. Investors are also buoyed by the number of investors in a company, with Sangamo Therapeutics Inc. having a total of 289 institutions that hold shares in the company. The top two institutional holders are Wasatch Advisors Inc with over 10.33 million shares worth more than $129.42 million. As of Mar 30, 2021, Wasatch Advisors Inc held 7.18% of shares outstanding.
The other major institutional holder is Blackrock Inc., with the holding of over 9.79 million shares as of Mar 30, 2021. The firm’s total holdings are worth over $122.64 million and represent 6.80% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Wasatch Ultra Growth Fund. As of May 30, 2021, the former fund manager holds about 3.02% shares in the company for having 4.34 million shares of worth $46.79 million while later fund manager owns 3.62 million shares of worth $45.35 million as of Mar 30, 2021, which makes it owner of about 2.52% of company’s outstanding stock.